Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer

Conclusion. Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety. The baseline NLR was predictive of efficacy, and a low baseline NLR (HR: 0.2895, P  = 0.0084) was associated with improved OS.Clinical Research Registration Number: ChiCTR1800015308.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research